Invitrogen™
life technologies

```
1    GTTGACATTG ATTATTGACT AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCATA

                            enhancer region (5' end)
61   GCCCATATAT GGAGTTCCGC GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC

121  CCAACGACCC CCGCCCATTG ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG

181  GGACTTTCCA TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCCAC TTGGCAGTAC

241  ATCAAGTGTA TCATATGCCA AGTCCGCCCC CTATTGACGT CAATGACGGT AAATGGCCCG

301  CCTGGCATTA TGCCCAGTAC ATGACCTTAC GGGACTTTCC TACTTGGCAG TACATCTACG

361  TATTAGTCAT CGCTATTACC ATGGTGATGC GGTTTTGGCA GTACACCAAT GGGCGTGGAT
                 AP1
421  AGCGGTTTGA CTCACGGGGA TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT
     enhancer region (3' end)
481  TTTGGCACCA AAATCAACGG GACTTTCCAA AATGTCGTAA TAACCCCGCC CCGTTGACGC
     CAAT                                          TATA
541  AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG CAGAGCTCGT TTAGTGAACC
                                                   pCEP Forward primer
     Transcriptional start          Kpn I Pvu II Nhe I   Hind III   Nhe I   Not I   Xho I
601  GTCAGATCTC TAGAAGCTGG GTACCAGCTG CTAGCAAGCT TGCTAGCGGC CGCTCGAGGC
       Sfi I     BamH I                                  EBV Reverse primer
661  CGGCAAGGCC GGATCCAGAC ATGATAAGAT ACATTGATGA GTTTGGACAA ACCACAACTA
```